Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 358

1.

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC.

Urol Clin North Am. 2001 Aug;28(3):555-65. Review.

PMID:
11590814
2.

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.

Pound CR, Partin AW, Epstein JI, Walsh PC.

Urol Clin North Am. 1997 May;24(2):395-406.

PMID:
9126237
3.

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.

J Urol. 2003 Feb;169(2):517-23.

PMID:
12544300
4.

Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.

Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC.

Urol Clin North Am. 1993 Nov;20(4):713-25.

PMID:
7505980
5.

Impact of surgical delay on long-term cancer control for clinically localized prostate cancer.

Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW.

J Urol. 2004 Nov;172(5 Pt 1):1835-9.

PMID:
15540733
6.

Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

Khan MA, Han M, Partin AW, Epstein JI, Walsh PC.

Urology. 2003 Jul;62(1):86-91; discussion 91-2.

PMID:
12837428
7.
8.

Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?

Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW.

Urology. 2001 Nov;58(5):746-51.

PMID:
11711353
9.

Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.

Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ.

Cancer. 2006 Sep 15;107(6):1265-72.

10.

Radical prostatectomy for clinical stage T3a disease.

Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.

Cancer. 2007 Apr 1;109(7):1273-8.

11.

Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.

Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ.

Urology. 2004 Oct;64(4):723-8.

PMID:
15491709
12.

Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM.

J Urol. 1994 Nov;152(5 Pt 2):1850-7.

PMID:
7523733
13.
14.
15.

Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.

Fair WR, Betancourt JE.

Mol Urol. 2000 Fall;4(3):241-8;discussion 249-50.

PMID:
11062380
16.

Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.

Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr, Skinner DG.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):600-9.

PMID:
12062603
17.
18.

Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.

Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC.

Urology. 2003 Nov;62(5):866-71.

PMID:
14624910
19.

Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.

Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D.

J Urol. 2001 Oct;166(4):1328-31; discussion 1331-2.

PMID:
11547067
20.

Supplemental Content

Support Center